Photocure ASA
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced ce… Read more
Photocure ASA - Asset Resilience Ratio
Photocure ASA (PHCUF) has an Asset Resilience Ratio of 27.13% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how Photocure ASA's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Photocure ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $200.51 Million | 27.13% |
| Total Liquid Assets | $200.51 Million | 27.13% |
Asset Resilience Insights
- Very High Liquidity: Photocure ASA maintains exceptional liquid asset reserves at 27.13% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Photocure ASA Industry Peers by Asset Resilience Ratio
Compare Photocure ASA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Photocure ASA (2013–2024)
The table below shows the annual Asset Resilience Ratio data for Photocure ASA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 27.13% | $200.51 Million | $739.09 Million | +24.47pp |
| 2023-12-31 | 2.66% | $18.96 Million | $711.97 Million | -29.91pp |
| 2022-12-31 | 32.57% | $234.20 Million | $719.03 Million | -0.36pp |
| 2021-12-31 | 32.93% | $260.06 Million | $789.65 Million | -2.41pp |
| 2020-12-31 | 35.34% | $274.25 Million | $776.05 Million | +0.50pp |
| 2019-12-31 | 34.84% | $89.67 Million | $257.35 Million | +0.62pp |
| 2018-12-31 | 34.22% | $79.11 Million | $231.20 Million | -4.16pp |
| 2017-12-31 | 38.38% | $100.98 Million | $263.10 Million | -11.18pp |
| 2016-12-31 | 49.56% | $141.66 Million | $285.85 Million | +3.88pp |
| 2015-12-31 | 45.68% | $113.31 Million | $248.06 Million | +36.15pp |
| 2014-12-31 | 9.53% | $25.79 Million | $270.58 Million | +9.49pp |
| 2013-12-31 | 0.04% | $117.00K | $301.73 Million | -- |